Mutch D, Voulgari A, Chen XM, Bradley WH, et al. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. Cancer 2024 Jan 30. doi: 10.1002/cncr.35222.
PMID: 38288862